公安机关已介入！思创医惠欺诈发行案或升级到刑事追责，前董事长章笠中独家回应

Core Viewpoint - Sichuang Medical's fraudulent issuance of securities has led to administrative penalties and ongoing criminal investigations, raising concerns about the company's governance and financial stability [1][6][7] Group 1: Fraudulent Issuance and Penalties - Sichuang Medical was penalized by the Zhejiang Securities Regulatory Commission in January 2024 for fraudulent issuance of securities, resulting in fines totaling 85.7 million yuan and a 10-year market ban for the former chairman [4][5] - The fraudulent activities included inflating revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflating revenue by 96.47 million yuan and profits by 83.94 million yuan in 2020 [3][4] Group 2: Ongoing Investigations - The Hangzhou Public Security Bureau has initiated a criminal investigation into the fraudulent issuance case, indicating potential criminal charges against responsible individuals [6][7] - The company has stated that the investigation is still in progress and does not currently have a significant impact on its operations [2][6] Group 3: Corporate Governance Changes - Following the fraud case, Sichuang Medical underwent significant governance changes, including the exit of key personnel and the entry of state-owned investors, which has led to a more stable operational environment [2][5] - The company reported a decline in revenue from 11.16 billion yuan in 2021 to 6.91 billion yuan in 2024, with net losses persisting over the years [4][5] Group 4: Market Reactions - The news of the criminal investigation led to a 10.08% drop in Sichuang Medical's stock price on August 18 [6][7] - The resignation of the vice president due to personal reasons amid the ongoing investigation has raised further speculation in the market [7]